Parker Waichman LLP Comments on Growing Public Attention Surrounding GLP-1 Vision Loss Litigation
Growing litigation focuses on the alleged causal association between GLP-1 medications and non-arteritic anterior ischemic optic neuropathy (NAION). PORT WASHINGTON, N.Y., July 21, 2026 /PRNewswire/ -- Parker Waichman LLP today commented on the growing public attention surrounding...
Growing litigation focuses on the alleged causal association between GLP-1 medications and non-arteritic anterior ischemic optic neuropathy (NAION). PORT WASHINGTON, N.Y., July 21, 2026 /PRNewswire/ -- Parker Waichman LLP today commented on the growing public attention surrounding...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.